Casdin Capital, LLC Verve Therapeutics, Inc. Transaction History
Casdin Capital, LLC
- $1.29 Billion
- Q3 2024
A detailed history of Casdin Capital, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 3,995,571 shares of VERV stock, worth $21.5 Million. This represents 1.5% of its overall portfolio holdings.
Number of Shares
3,995,571
Previous 3,059,094
30.61%
Holding current value
$21.5 Million
Previous $14.9 Million
29.54%
% of portfolio
1.5%
Previous 1.29%
Shares
10 transactions
Others Institutions Holding VERV
# of Institutions
186Shares Held
73.3MCall Options Held
85KPut Options Held
183K-
Alphabet Inc. Mountain View, CA12.3MShares$66.4 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$35.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$26.7 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$22.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$21.5 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $322M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...